supplementary table 1

9
Supplementary Table 1 A. B. CI simulations display synergism (CI < 1), additive effect (CI = 1), or antagonism (CI > 1) for the entire spectrum of effect levels (Fa) in the combination of NFV and BZ (right panel). CIs for experimental values (left panel) are displayed as actual Fa-CI plots in Figure 1B. CIs for experimental values are displayed as actual Fa-CI plots in Figure 1D.

Upload: braeden-lane

Post on 31-Dec-2015

21 views

Category:

Documents


0 download

DESCRIPTION

Supplementary Table 1. A. - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Supplementary Table 1

Supplementary Table 1

A.

B.

CI simulations display synergism (CI < 1), additive effect (CI = 1), or antagonism (CI > 1) for the entire spectrum of effect levels (Fa) in the combination of NFV and BZ (right panel). CIs for experimental values (left panel) are displayed as actual Fa-CI plots in Figure 1B.

CIs for experimental values are displayed as actual Fa-CI plots in Figure 1D.

Page 2: Supplementary Table 1

Per

cen

t su

b-G

1 D

NA

Per

cen

t ce

ll d

eath

DMSO NFV Bortezomib NFV+Bortezomib DMSO NFV Bortezomib NFV+Bortezomib

DMSONFVBortezomibZ-VAD

PARPCleaved PARP

+---

+ ++

+ + + ++ +-

-

- - - - - -- -

- -+ - + - + - +

- Z-VAD

+ Z-VAD

- Z-VAD

+ Z-VAD*

*

RPMI8226 RPMI8226

Supplementary Figure 1

Page 3: Supplementary Table 1

H157

DR5 precursor

DR4

DR5 mature

α-Tubulin

Bcl-2

Bax

Fas

NFVDMSO

Bortezomib -

0.5 h 8 h 24 h

- + + - - + + - - + +- + - + - + - + - + - ++ - - - + - - - + - - -

Mcl-1

Actin

Supplementary Figure 2

Page 4: Supplementary Table 1

P-Akt (S473)

Total Akt

P-Akt (T308)

P-p44/42

α-Tubulin

P-JNK (54/46 kDa)

P-p38

Total p44/42

Total p38

NFVDMSO

Bortezomib -

0.5 h 8 h 24 h

- + + - - + + - - + +- + - + - + - + - + - ++ - - - + - - - + - - -

H157

Supplementary Figure 3

Page 5: Supplementary Table 1

P-eIF2α

ATF3

2 43 5

Vehicle NFV

GAPDH

1

Bortezomib

CHOP

C1

PARP

C2

Bip

Total-eIF2α

XBP-1s

Cleaved PARP

Caspase 3

Cleaved Caspase 3

Cleaved Caspase 3Cleaved Caspase 3

2 43 51 2 43 51 2 43 51

NFV+Bortezomib

H157 Xenograft tumor lysates

Supplementary Figure 4

A.

Page 6: Supplementary Table 1

HSP70

Ubiqutin

2 43 5

Vehicle NFV

GAPDH

1

Bortezomib NFV+Bortezomib

C1 C2 2 43 51 2 43 51 2 43 51

H157 Xenograft tumor lysates

B.

Page 7: Supplementary Table 1

RPMI8226 Xenograft tumor lysates

C.

ATF3

V N Bz N+BzEx

pre

ss

ion

ra

tio

to

ve

hic

le

CHOP

Ex

pre

ss

ion

ra

tio

to

ve

hic

le

V N Bz N+Bz

Page 8: Supplementary Table 1

Supplementary Figure 5

Page 9: Supplementary Table 1

Supplementary Figure 6